Patents by Inventor Christopher Boyce
Christopher Boyce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11874280Abstract: Compositions comprising fluorescent or colored dyes and methods of using the same in combination with divalent metal salts to analyze samples are disclosed.Type: GrantFiled: March 8, 2019Date of Patent: January 16, 2024Assignee: Sony Group CorporationInventors: Melissa Jackson, Christopher Boyce, Eriko Matsui, Michael Vanbrunt, Sharat Singh, Tracy Matray
-
Publication number: 20210109104Abstract: Compositions comprising fluorescent or colored dyes and methods of using the same in combination with divalent metal salts to analyze samples are disclosed.Type: ApplicationFiled: March 8, 2019Publication date: April 15, 2021Inventors: Melissa JACKSON, Christopher BOYCE, Eriko MATSUI, Michael VANBRUNT, Sharat SINGH, Tracy MATRAY
-
Patent number: 10011615Abstract: Disclosed are compounds of Formula G1: where “RG3”. “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein, which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.Type: GrantFiled: February 2, 2017Date of Patent: July 3, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
-
Patent number: 9926601Abstract: The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.Type: GrantFiled: February 24, 2012Date of Patent: March 27, 2018Assignees: Massachusetts Institute of Technology, Montefiore Medical Center, Albert Einstein College of Medicine, Inc.Inventors: Frank B. Gertler, Christopher Boyce Burge, Irina M. Shapiro, Wu Albert Cheng, John S. Condeelis, Maja H. Oktay
-
Patent number: 9884048Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.Type: GrantFiled: December 10, 2015Date of Patent: February 6, 2018Assignee: MERCK SHARP & DOHME CORP.Inventors: Phieng Siliphaivanh, Joey Methot, Kathryn Ann Lipford, Danielle Molinari, David L. Sloman, David Witter, Hua Zhou, Christopher Boyce, Xianhai Huang, Jongwon Lim, David Guerin, Ganesh Babu Karunakaran, Raman Kumar Bakshi, Ziping Liu, Jianmin Fu, Zhilong Wan, Wei Liu
-
Publication number: 20170266167Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 10, 2015Publication date: September 21, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Phieng Siliphaivanh, Joey Methot, Kathryn Ann Lipford, Danielle Molinari, David L. Sloman, David Witter, Hua Zhou, Christopher Boyce, Xianhai Huang, Jongwon Lim, David Guerin, Ganesh Babu Karunakaran, Raman Kumar Bakshi, Ziping Liu, Jianmin Fu, Zhilong Wan, Wei Liu
-
Publication number: 20170197991Abstract: Disclosed are compounds of Formula G1: where “RG3”. “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein, which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.Type: ApplicationFiled: February 2, 2017Publication date: July 13, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
-
Patent number: 9676780Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.Type: GrantFiled: December 20, 2013Date of Patent: June 13, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Michael Berlin, Pauline Ting, Gang Zhou, Tao Yu, Christopher Boyce, Joseph Michael Kelly, Jayaram R. Tagat, Junying Zheng, Xianhai Huang, Wei Zhou, Jae-Hun Kim, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Rajan Anand, Qiaolin Deng
-
Patent number: 9513175Abstract: An apparatus for spatially correcting an image frame is disclosed. In some embodiments, the apparatus stores a frame of pixel values and scans a multi-pixel correction window across the frame. Spatial correction is performed on pixels within the window at correction positions during the scan. The spatial correction comprises estimating pixel values at value estimation positions based on one or more pixel values within the window for pixels satisfying a logical condition. The value estimation positions correspond to pixel values which do not fall within the window again during the scan. Further disclosed is an apparatus for detecting high-energy radiation, in which integration circuitry is used for integrating charge responsive to radiation photon interaction events. The circuits are controllable in accordance with an exposure control signal to vary an exposure window duration according to an operating parameter of the apparatus.Type: GrantFiled: June 3, 2016Date of Patent: December 6, 2016Assignee: RADIATION WATCH LIMITEDInventors: David Prendergast, Michael Anderson, Paul Downes, William Croydon, Christopher Boyce, Wayne Cranwell, Trevor McAlister, Zhuo Zhhang
-
Publication number: 20160313456Abstract: An apparatus for spatially correcting an image frame is disclosed. In some embodiments, the apparatus stores a frame of pixel values and scans a multi-pixel correction window across the frame. Spatial correction is performed on pixels within the window at correction positions during the scan. The spatial correction comprises estimating pixel values at value estimation positions based on one or more pixel values within the window for pixels satisfying a logical condition. The value estimation positions correspond to pixel values which do not fall within the window again during the scan. Further disclosed is an apparatus for detecting high-energy radiation, in which integration circuitry is used for integrating charge responsive to radiation photon interaction events. The circuits are controllable in accordance with an exposure control signal to vary an exposure window duration according to an operating parameter of the apparatus.Type: ApplicationFiled: June 3, 2016Publication date: October 27, 2016Inventors: David Prendergast, Michael Anderson, Paul Downes, William Croydon, Christopher Boyce, Wayne Cranwell, Trevor McAlister, Zhuo Zhhang
-
Publication number: 20160194330Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.Type: ApplicationFiled: December 20, 2013Publication date: July 7, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Michael Berlin, Pauline Ting, Gang Zhou, Tao Yu, Christopher Boyce, Joseph Michael Kelly, Jayaram R. Tagat, Junying Zheng, Xianhai Huang, Wei Zhou, Jae-Hun Kim, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Rajan Anand, Qiaolin Deng
-
Patent number: 9233979Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).Type: GrantFiled: September 26, 2013Date of Patent: January 12, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Kevin J. Wilson, David J. Witter, Phieng Siliphaivanh, Kathryn Lipford, David Sloman, Danielle Falcone, Brendan O'Boyle, Umar Faruk Mansoor, Jongwon Lim, Joey L. Methot, Christopher Boyce, Lei Chen, Matthew H. Daniels, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Ling Tong, Wei Zhou, Joseph Kozlowski, Milana M. Maletic, Bidhan A. Shinkre, Jayanth Thiruvellore Thatai, Raman Kumar Bakshi, Ganesh Babu Karunakaran
-
Patent number: 9226922Abstract: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).Type: GrantFiled: September 26, 2013Date of Patent: January 5, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Kevin J. Wilson, David J. Witter, Matthew H. Daniels, Angie R. Angeles, Phieng Siliphaivanh, David Sloman, Brendan O'Boyle, Danielle Falcone, Catherine White, Ron Ferguson, Wei Zhou, Kathryn Lipford, Umar Faruk Mansoor, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Judson E. Richard, Shuyi Tang, Christopher Boyce, Joseph Kozlowski, Raman Kumar Bakshi, Ganesh Babu Karunakaran
-
Publication number: 20150361098Abstract: Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.Type: ApplicationFiled: December 20, 2013Publication date: December 17, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
-
Publication number: 20150266895Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).Type: ApplicationFiled: September 26, 2013Publication date: September 24, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Kevin J. Wilson, David J. Witter, Phieng Siliphaivanh, Kathryn Lipford, David Sloman, Danielle Falcone, Brendan O'Boyle, Umar Faruk Mansoor, Jongwon Lim, Joey L. Methot, Christopher Boyce, Lei Chen, Matthew H. Daniels, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Ling Tong, Wei Zhou, Joseph Kozlowski, Milana M. Maletic, Bidhan A. Shinkre, Jayanth Thiruvellore Thatai, Raman Kumar Bakshi, Ganesh Babu Karunakaran
-
Publication number: 20150258074Abstract: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).Type: ApplicationFiled: September 26, 2013Publication date: September 17, 2015Applicant: MERCK SHARP & DOHME CORP.Inventors: Kevin J. Wilson, David J. Witter, Matthew H. Daniels, Angie R. Angeles, Phieng Siliphaivanh, David Sloman, Brendan O'Boyle, Danielle Falcone, Catherine White, Ron Ferguson, Wei Zhou, Kathryn Lipford, Umar Faruk Mansoor, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Judson E. Richard, Shuyi Tang, Christopher Boyce, Joseph Kozlowski, Raman Kumar Bakshi, Ganesh Babu Karunakaran
-
Publication number: 20150083925Abstract: An apparatus for spatially correcting an image frame is disclosed. In some embodiments, the apparatus stores a frame of pixel values and scans a multi-pixel correction window across the frame. Spatial correction is performed on pixels within the window at correction positions during the scan. The spatial correction comprises estimating pixel values at value estimation positions based on one or more pixel values within the window for pixels satisfying a logical condition. The value estimation positions correspond to pixel values which do not fall within the window again during the scan. Further disclosed is an apparatus for detecting high-energy radiation, in which integration circuitry is used for integrating charge responsive to radiation photon interaction events. The circuits are controllable in accordance with an exposure control signal to vary an exposure window duration according to an operating parameter of the apparatus.Type: ApplicationFiled: April 30, 2014Publication date: March 26, 2015Applicant: RADIATION WATCH LIMITEDInventors: David Prendergast, Michael Anderson, Paul Downes, William Croydon, Christopher Boyce, Wayne Cranwell, Trevor McAlister, Zhuo Zhhang
-
Publication number: 20140066319Abstract: The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.Type: ApplicationFiled: February 24, 2012Publication date: March 6, 2014Applicants: Massachusetts Institute of Technology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva UniversityInventors: Frank B. Gertler, Christopher Boyce Burge, Irina M. Shapiro, Wu Albert Cheng, John S. Condeelis, Maja H. Oktay
-
Patent number: 8335515Abstract: A communications system includes remote stations coupled to a central station by a network. The system includes the network, the central station establishes a list of information about available network resources and publishes the list for the remote station. The system includes the remote stations, which identify a set of said published resources needed to establish the connection, notify the central station about the identified resources, and seize the set of identified resources to thereby establish the connection. The central station updates the list of available resources to thereby reflect the seizing of the set, and communicates the updated list to the remote stations.Type: GrantFiled: March 9, 2012Date of Patent: December 18, 2012Assignee: Thiss Technologies Pte LtdInventors: Thomas Earle Goerke, Richard Harold Hammersla, Nicholas Richard Hart, Christopher Boyce Meulman, Nicholas Antony Cirillo
-
Publication number: 20120230300Abstract: A communications system includes remote stations coupled to a central station by a network. The system includes the network, the central station establishes a list of information about available network resources and publishes the list for the remote station. The system includes the remote stations, which identify a set of said published resources needed to establish the connection, notify the central station about the identified resources, and seize the set of identified resources to thereby establish the connection. The central station updates the list of available resources to thereby reflect the seizing of the set, and communicates the updated list to the remote stations.Type: ApplicationFiled: March 9, 2012Publication date: September 13, 2012Applicant: THISS TECHNOLOGIES PTE LTDInventors: Thomas Earle Goerke, Richard Harold Hammersla, Nicholas Richard Hart, Christopher Boyce Meulman, Nicholas Antony Cirillo